OCA
PSTV

Otter Creek Advisors’s Plus Therapeutics PSTV Stock Holding History

Otter Creek Advisors’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-880
Closed -$147K – 52
2022
Q3 		$147K Hold
880
– – 0.12% 45
2022
Q2 		$178K Buy
880
+656
+293% +$164K 0.12% 40
2022
Q1 		$84K Buy
+224
New +$85.2K 0.03% 58

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GVAG
Great Valley Advisor Group Wilmington, Delaware $5.5B AUM 20.56% 1-Year Est. Return

Otter Creek Advisors's PSTV Position: Q4 2022 in Review

Otter Creek Advisors sold out of Plus Therapeutics (PSTV) in Q4 2022, closing a stake of 880 shares — an estimated $147K sold.

Otter Creek Advisors first reported a position in PSTV in Q1 2022 and held it in 3 quarters. The position peaked at $178K in Q2 2022. 22 funds tracked by Wall St. Rank hold PSTV as of Q4 2022.

  • Otter Creek Advisors reported no remaining Plus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Otter Creek Advisors sold 880 Plus Therapeutics shares in Q4 2022, an estimated $147K.
  • Otter Creek Advisors first reported a position in Plus Therapeutics in Q1 2022 and held it in 3 quarters.
  • Otter Creek Advisors's Plus Therapeutics position peaked at $178K in Q2 2022.
  • 22 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2022.

Based on Otter Creek Advisors's 13F filing for Q4 2022, filed 31 Jan 2023.